
VON HIPPEL-LINDAU DISEASE: THE CLINICAL
MANIFESTATIONS AND GENETIC ANALYSIS RESULTS
OF TWO CASES FROM A SINGLE FAMILY Kinyas S1, Ozal SA1,*, Guclu H1, Gurlu V1, Esgin H1, Gurkan H2 *Corresponding Author: Dr. Sadık Altan Ozal, Trakya Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim
Dalı, Edirne 22030, Turkey. Tel: +90-505-450-42-67. Fax: +90-284-223-55-06. E-mail: altanozal@hotmail.com page: 65
|
INTRODUCTION
von Hippel-Lindau (VHL) (MIM#193300) disease
is an autosomal dominant inherited disorder that
is classically associated with benign or malignant
tumors in multiple organs. The most frequent tumors
are retinal hemangioblastoma (RH) and central nervous
system (CNS) hemangioblastomas, renal cell
carcinoma (RCC), pheochromocytoma, pancreatic
islet cell tumors and endolymphatic sac tumours [1].
von Hippel-Lindau disease most commonly presents
between the ages of 25 and 40, and the prevalence
of the disease is 1 in 35000 [2]. Retinal hemangioblastoma
is the most frequent neoplasm and the most
common clinical sign of the disease; it is seen in 40.0-
60.0% of patients [1]. Retinal hemangioblastomas are
benign tumors that may be localized peripherally or
juxtapapillary and show a slow-growing pattern [3].
In 1993, mutational inactivation of tumor suppressor
genes in chromosome 3p25-p26 were found
to be responsible for VHL [4]. The VHL coding sequence
is represented in three exons and encodes two
VHL proteins [5]. The VHL gene functions as a tumor
suppressor gene, and leads to neoplastic transformation
when inactivated by the mutation that causes loss
of function [6]. As a result of existing studies, many
different VHL gene point mutations, recombinations
and deletions have been identified. In recent years,
studies of patients with VHL have tried to establish the relationship between genotype and phenotype
[7]. In this study, two cases of VHL from a single
family are presented with renal and CNS involvement
in addition to RH, which were not presented in this
kind of mutation.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|